| Identification | Back Directory | [Name]
SESELIN | [CAS]
523-59-1 | [Synonyms]
Sesalin
8,8-dimethylpyrano[2,3-f]chromen-2-one
8,8-dimethylpyrano[2,3-h]chromen-2-one
2,2-Dimethyl-1,5-dioxaphenanthrene-6(2H)-one
8,8-Dimethyl-2H,8H-pyrano[2,3-f]chromen-2-one
8,8-Dimethyl-2H,8H-benzo[1,2-b:3,4-b']dipyran-2-one
2H,8H-Benzo[1,2-b:3,4-b']dipyran-2-one, 8,8-dimethyl- | [Molecular Formula]
C14H12O3 | [MDL Number]
MFCD01018179 | [MOL File]
523-59-1.mol | [Molecular Weight]
228.24 |
| Chemical Properties | Back Directory | [Melting point ]
119-124 °C | [Boiling point ]
403.0±45.0 °C(Predicted) | [density ]
1.351 g/cm3(Temp: 18 °C) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
A solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Seselin is a coumarin compound that can be isolated from the root bark of the Citropsis articulata plant. Studies show that Seselin might exhibit potential antimalarial activity and that its derivatives may exhibit antithrombotic activity. | [Definition]
ChEBI: A natural product found in Citropsis articulata. | [Biological Activity]
Seselin is an anti-inflammatoryanti-parasitic and antifungal pyrancoumarin found in anise and other plants. It appears th at seselin targets Jak2 to block the proinflammatory phenotype of macrophages in models of sepsis. Seselin down-regulates levels of proinflammatory factors and activity of STAT1 and p65 in models of sepsis. | [in vivo]
Seselin (0.5-40.5 mg/kg; s.c.; once) shows peripheral anti-inflammatory and antinociceptive activities in mice[2].
Seselin (3-30 mg/kg; i.g.; once) ameliorates sepsis induced by caecal ligation and puncture in mice[3]. | Animal Model: | Male Swiss mice[2] | | Dosage: | 0.5, 4.5 or 40.5 mg/kg | | Administration: | Subcutaneous injection; once | | Result: | Inhibited the writhing response induced by acetic acid in a significant and dose-dependent manner, by 19.5%, 26.2% and 41.4% at dose of 0.5, 4.5 or 40.5 mg/kg, respectively. Elicited a significant inhibition of formalin response during the second phase (inflammatory), by 90.3%, 97.8% and 95.3%, respectively. |
| Animal Model: | C57BL/6 mice, caecal ligation and puncture (CLP) induced sepsis model[3] | | Dosage: | 3, 10 and 30 mg/kg | | Administration: | Intragastric administration, once | | Result: | Ameliorated lung injury and decreased JAK2 phosphorylation level in lung tissue during sepsis. Reduced the immune cell counts in BALF induced by CLP.
|
|
|
|